拓普替康治疗卵巢癌的循证评价  

Evidence - based Management of topotecan for patients with ovarian cancer

作　　者：陈洪 

机构地区：[1]四川省南充市高坪区妇幼保健院,637100

出　　处：《中国医学创新》2010年第18期11-13,共3页Medical Innovation of China

摘　　要：目的采用循证医学的方法评价拓普替康治疗卵巢癌的效果和安全性。方法采用Cochrane系统评价方法，检索Cochrane图书馆，MEDLINE，CENTRAL，CNKI，VIP，CBMDISC等电子资料库，搜集关于拓普替康治疗卵巢癌的系统评价、临床随机对照试验等，并对所获取的证据进行质量评价。结果检索并纳入7篇临床随机对照试验，1篇系统评价。根据临床问题，对所查证据进行了评价。结论拓普替康与紫杉醇、甲基化脂质体阿霉素、吉西他滨等化疗药具有相似的治疗作用，是一种有效的治疗卵巢癌的二线化疗药物。Objective Method of evidence - based medicine were used to discuss the effectiveness and safety of topo- tecan in the treatment of women with ovarian cancer. Methods To find the current best evidence of management of topotcean for patients with ovarian cancer,we have searched the Cochrane Library, MEDLINE, Cochrane Central Register of Controlled Trials（CENTRAL） , China National Knowledge Infrastructure databases（CNKI） , VIP, CBMDISC, in order to get the systematic review and randomized controlled trails（RCT） of management of topotecan for patients with ovarian cancer, and further criti- cally apprcased the available evidence. Results Seven RCT and one systematic review had been selected. Based on the clinical problem,we had searched for and asscessed the evidence. Conclusion Topotecan appears to have a similar level of effec- tiveness as paelitaxel and pcgylated liposomal doxorubiein（PLD） , though with different patterns of side effects.

关 键 词：拓普替康 卵巢癌 循证治疗 I艋床证据 

分 类 号：R285.5[医药卫生—中药学]